Long-Acting Hydrocortisone for Glucocorticoid Replacement Therapy
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: Glucocorticoid (GC) deficiency is a consequence of various disorders that are by themselves rare. Because of this low prevalence, the low cost of GC replacement therapy and the belief that existing outcomes are good, there has been little interest in development of new and improved pharmaceutical products for treatment of GC deficiency. However, GC replacement therapy is complex: diurnal variation of endogenous cortisol must be replicated, GC needs may change during times of physical and psychological stress and there is no biomarker of its action that can be used to monitor individual dose response. Current Limitations: Recent data suggest that the outcome of established long-term GC replacement therapy may not be as good as previously believed. Short-acting GCs such as hydrocortisone (HC) and cortisone acetate for replacement therapy require 2 to 3 administrations per day. Developing Alternatives: Drug delivery system technologies are now available that could permit design and manufacture of a formulation that could accommodate once-daily administration of HC. Such a formulation would enable more physiological serum cortisol-time profiles than are possible with currently available formulations. This short review provides some background on GC replacement therapy, along with recent data on the outcome of patient groups with GC insufficiency, and briefly discusses some general principles for a controlled-release (‘long-acting’) HC formulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects
WEITZMAN, E. D., FUKUSHIMA, D., NOGEIRE, C., ROFFWARG, H., GALLAGHER, T. F., & HELLMAN, L. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-1-14 · Cited by 1,258
Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency
Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411401 · Cited by 644
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 1×
“Therefore, the survival rate is considered to be normal or comparable to normal for patients receiving replacement therapy and adequate follow-up.We tested this hypothesis by investigating the standardized mortality rate of patients in Sweden who required life-long daily treatment with GC replacement therapy for Addis…”
BackgroundSelf-citationHunt, P. J., Gurnell, E. M., Huppert, F. A., Richards, C., Prevost, A. T., Wass, J. A. H., Herbert, J., & Chatterjee, V. K. K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7022 · Cited by 386
Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain
Regal, M., Páramo, C., Sierra, J. M., & García‐Mayor, R. V. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01406.x · Cited by 354
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 1×
“However, most estimates of dose equivalency among GCs are based on the anti-inflammatory effects and, thus, these estimates cannot reflect all metabolic aspects of GC replacement therapy.We evaluated the metabolic outcomes of different GC replacement therapies by comparing a large group of adult adrenocorticotropic ho…”
MethodSelf-citationMah, P. M., Jenkins, R. C., Rostami‐Hodjegan, A., Newell‐Price, J., Doane, A., Ibbotson, V., Tucker, G. T., & Ross, R. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02106.x · Cited by 243
Kerrigan, J. R., Veldhuis, J. D., Leyo, S. A., Iranmanesh, A., & Rogol, A. D. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501158 · Cited by 228
Cited by
Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients
Bleicken, B., Ventz, M., Quinkler, M., & Hahner, S. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181db6b7a · Cited by 242
Grossman, A., Johannsson, G., Quinkler, M., & Zelissen, P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0450 · Cited by 119
Self-citationØksnes, M., Bensing, S., Hulting, A.-L., Kämpe, O., Hackemann, A., Meyer, G., Badenhoop, K., Betterle, C., Parolo, A., Giordano, R., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1901 · Cited by 99
Therapeutic management of adrenal insufficiency
Hahner, S., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.009 · Cited by 61
Simon, N., Castinetti, F., Ouliac, F., Lesavre, N., Brue, T., & Oliver, C. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531290-000000000-00000 · Cited by 61
Metadata
- Authors
- Johannsson, G., Filipsson, H., Bergthorsdottir, R., Lennernäs, H., & Skrtic, S.
- Venue
- Hormone Research in Paediatrics
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 68
- Issue
- Suppl. 5
- Pages
- 182-188
- ISSN
- 1663-2818 (ISSN-L)
- 1663-2826
- OpenAlex
- W1977888148
- Cited by
- 23
- References
- 14
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Acting Hydrocortisone for Glucocorticoid Replacement Therapy. https://app.cochat.ai/papers/10.1159/000110621
- The paper
- Johannsson, G., Filipsson, H., Bergthorsdottir, R., Lennernäs, H., & Skrtic, S. (2007). Long-Acting Hydrocortisone for Glucocorticoid Replacement Therapy. Hormone Research in Paediatrics. https://doi.org/10.1159/000110621
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.